Viromed Medical AG plans to acquire all shares in ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights Pinneberg, 17 September 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus s [ … ]

Viromed Medical AG plans to acquire all shares in ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights Pinneberg, 17 September 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus s [ … ]

Viromed Medical AG: Successful start of trading on XETRA   Listing on leading German financial market increases liquidity and expands investor base Aiming to expand its pioneering role in the medical use of cold plasma technology Pinneberg, 2 September 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) has reached another mil [ … ]

Viromed Medical AG seeks special approval for cold plasma device for the prevention of ventilator-associated pneumonia (VAP) Targeted use of the antimicrobial effect of cold plasma beyond wound treatment Use of cold plasma could revolutionize the treatment of VAP and significantly reduce mortality Aiming for rapid special approval for own devic [ … ]

Viromed Medical AG: Viromed Medical GmbH and terraplasma medical GmbH terminate their cooperation with immediate effect Pinneberg, 5 July 2024 – Viromed Medical GmbH, a wholly owned subsidiary of Viromed Medical AG, and terraplasma medical GmbH have today terminated their business relation with immediate effect. As part of the previous cooperation [ … ]

Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care® by Viromed with significant growth potential Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusive use of the pioneering cold plasma therapy with Plasma Care® by V [ … ]

Viromed Medical AG concludes agreement with CORIUS Group for exclusive use of cold plasma therapy with Plasma Care® by Viromed – Additional earnings contribution of EUR 0.28 to EUR 0.34 per share expected from 2025 onwards Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusi [ … ]